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ADMA is a useful marker, but many 
confounding factors should be 
considered!
To the Editor,
We read the article entitled “Could plasma asymmetric dimethylar-
ginine level be a novel predictor beyond the classic predictors of stent 
restenosis?” by Bal et al. (1) published in Anatolian J Cardiol 2014; 14: 
491-7. The authors assessed the factors associated with coronary stent 
restenosis and if there is an association between plasma asymmetric 
dimethylarginine (ADMA) levels and stent restenosis. They concluded 
that plasma ADMA levels may be used as a novel marker for stent 
restenosis beyond the classic stent restenosis markers.
Novel inflammatory markers have been identified in recent years for 
stent restenosis. One of the major endothelium-derived vasoactive 
mediators is nitric oxide (NO). A growing body of data indicates that 
endogenous NO synthase inhibitors, like asymmetric dimethylarginine 
(ADMA), may be responsible for endothelial vasodilator dysfunction in 
many individuals with coronary and peripheral arterial diseases and in 
those with their risk factors, particularly hypertension, diabetes mellitus, 
hypercholesterolemia, hyperhomocysteinemia, smoking, and aging (2).
First, we have some comments on the present study. Renal failure 
is one of the most important prognostic variables in patients with car-
diovascular disease (3). ADMA is eliminated from the body via renal 
excretion. The glomerular filtration rate (GFR) provides more accurate 
knowledge about renal function than the serum creatinine level. A mild 
reduction in GFR is associated with an increased plasma level of 
ADMA. The Cockcroft-Gault equation (CGE) and the modification of diet 
in renal disease (MDRD) are methods for calculating the GFR. However, 
the CGE and MDRD may estimate different values of GFR according to 
age (4). Instead of using these methods, the Berlin Initiative Study (BIS) 
equation (which estimates the GFR more precisely) or Chronic Kidney 
Disease-Epidemiology Collaboration (CKDEPI) are more useful methods 
in recent studies (5). 
Second, the authors said that plasma ADMA levels were analyzed 
by using high-performance liquid chromatography (HPLC). This novel 
assay allows the rapid, reproducible, and available sensitive determina-
tion of ADMA compared with ELISA method (2), but many assays are 
time-consuming and costly and deliver quite unstable results, which are 
not suitable to differentiate ADMA from SDMA, NMMA, and other 
methylated arginine analogs. They did not determine other arginine 
derivatives, such as symmetric dimethylarginine and L-arginine, or 
assess endothelial function. For this reason, HPLC coupled to mass 
spectrometric detection (LC-MS/MS) has the clear advantage to be the 
current gold standard for the differentiation between ADMA and the 
other methylated arginine derivatives; however, this method is not 
widely available, and the equipment is comparatively expensive (6).
Furthermore, they used coronary angiography to assess coronary 
artery stenosis; however, intravascular ultrasonography is the best 
method to demonstrate neointimal tissue burden completely. They also 
did not measure other relevant biomarkers, such as homocysteine, 
lipoprotein (a), and lipoprotein-associated phospholipase A2. 
As a conclusion, ADMA is clearly tightly related to oxidative-
inflammatory mechanisms of atherosclerosis, and it would have been 
very helpful to have measured other relevant biomarkers, such as 
C-reactive protein, homocysteine, lipoprotein (a), and lipoprotein-
associated phospholipase A2, to help define that the 2 groups were 
adequately matched, whether ADMA tracks simply as a covariate with 
these other biomarkers, and whether differences in ADMA survive and 
remain statistically significant after adjusting for them (7).
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